Drug Bulletin - January 2004
Help on accessing alternative formats, such
as PDF, MP3 and WAV files, can be obtained in the alternate
format help section.
(69.7 KB)
The Non-Insured Health Benefits (NIHB) Program
provides supplementary
health benefits, including prescription and non-prescription drugs,
for
registered Indians, and recognized Inuit and Innu throughout Canada.
Open Benefits
(Effective November 1, 2003)
1. Bimatoprost, ophthalmic solution , 0.03%,(Lumigan®-Allergan
Inc.)
Bimatoprost is indicated for the reduction of intraocular pressure
in patients with open angle glaucoma or ocular hypertension.
2. Insulin Aspart, injectable, 100 U/ml,(NovoRapid® -NovoNordisk)
This agent is indicated for the treatment of diabetes mellitis.
3. Perindopril erbumine/indapamide, tablet, 4 mg/1.25
mg (Coversyl Plus®-Servier Canada Inc., formerly called Biprel®)
This combination product is indicated for the treatment of mild
to moderate hypertension.
4. Rosuvastatin, tablet, 10 mg, 20 mg and 40 mg, (Crestor®-AstraZeneca)
Rosuvastatin is indicated as a lipid lowering agent.
5. Trandolapril, capsules, 1 and 2 mg,(Mavik-Abbott
Laboratories Ltd.)
Trandolapril is indicated for the treatment of mild to moderate
hypertension.
New Limited Use Benefits
(Prior approval required)
(Effective December 1, 2003)
1. Ribavarin and peginterferon alfa 2b, injectable,(Pegetron -
Schering Canada Inc.)
Pegetron will be a Limited Use Benefit for the treatment
of naive patients with active PCR confirmed Hepatitis C infection,
and no documented contraindications.
A. For genotype 1, 4, 5 and 6, an initial 14-week
supply will be approved. A maximum further 34- week supply may
be approved, if patient has a viral reduction of at least 2 logs
or HCV is undetectable at 12 weeks (for a total of 48-weeks treatment).
B. For genotype 2 or 3, initial coverage for
a maximum of 24 weeks may be approved. Renewals will not be covered.
2. Tiotropium, capsules for inhalation, 18 mcg,(Spiriva® -
Pfizer Canada Inc.)
Spiriva® will be a Limited Use Benefit for the following condition:
For the treatment of moderate* to severe* chronic obstructive
pulmonary disease (COPD), in patients who continue to be symptomatic
after an adequate trial (2-4 months) of ipatropium, at a dose of
4 puffs 4 times daily.
*Canadian Thoracic Society COPD Classification by Symptoms/Disability:
Moderate: shortness of breath from COPD causing
the patient to stop after walking about 100 meters (or after a
few minutes) on the level.
Severe: shortness of breath from COPD leaving
the patient too breathless to leave the house or breathless after
undressing, or in the presence of chronic respiratory failure or
clinical signs of right heart failure.
3. Valdecoxib, tablets, 10mg, (Bextra -Pharmacia
Canada Inc.)
Valdecoxib will be a limited use benefit for the following conditions:
For patients with osteoarthritis who have failed therapy with
acetaminophen and who:
A. have failed to achieve adequate response with
2 other listed NSAIDS, or
B. have experienced an adverse event attributable
to 2 other listed NSAIDS, or
C. have a history of a serious gastrointestinal
complication, such as bleeding or perforation.
For patients with rheumatoid arthritis who:
A. have failed to achieve adequate response with
2 other listed NSAIDS, or
B. have experienced an adverse event attributable
to 2 other listed NSAIDS, or
C. have a history of a serious gastrointestinal
complication such as bleeding or perforation.
4. Sirolimus, tablets, 1mg, (Rapamune®-WyethPharmaceuticals)
Benefit coverage will be provided as a second line therapy for
patients whose treatment using mycophenolate mofetil has failed.
NIHB Decision Not to Add the Following Drugs to the NIHB Drug
Benefit List After Review by the Federal Pharmacy and Therapeutics Committee
The following drugs will not be added to the NIHB Drug Benefit
List:
1. Desmopressin (Minirin®) 0.1 mg,0.2
mg tablets,(Ferring Pharmaceuticals)
2. Diclofenanc topical (Pennsaid®)1.5%
solution,(Dimethaid Health Care Ltd.)
3. Latanoprost/timolol) (Xalacom)
ophthalmic solution,(Pharmacia Canada)
4. Pimecrolimus (Elidel®)1% topical
cream,(Novartis Pharmaceuticals Canada Inc.)
5. Rosiglitazone/metformin (Avandamet)
tablets,(GlaxoSmithKline Inc.)
6. Trandolapril/verapamil (Tarka®)
tablets, (AbbotLaboratories Limited)
7. Valdecoxib 20 mg (Bextra) tablets,
(PharmaciaCanada Inc.)
Benefits Delisted from the NIHB Drug Benefit List:
Since November 27, 2003 all products containing nefazodone were
delisted from the NIHB DBL, following the discontinuation of sales
of nefazodone in Canada.
Quantity and Frequency Limits - Blood Glucose Test Strips
Effective February 1, 2004 , a quantity limitation will be implemented
for blood glucose test strips. The NIHB Program will reimburse
a total number of 5 test strips per day in a 100-day period (500
test strips per 100 days). All paid claims for blood glucose test
strips will be counted towards the maximum allowable quantity.
No prior approval will be required for the client to obtain the
allowable quantity within the specified period. Once the maximum
has been exceeded, a prior approval would be required. For coverage
details, please refer to the Web site at :
http://www.hc-sc.gc.ca/fnihb/nihb/pharmacy/drugbenefitlist/therapeutic_3600.pdf
Important Drug Safety Information regarding Paxil®
(The following is taken from the Therapeutics Products Directorate web site, dated2003-07-10).
Until further information is available, PAXIL® (paroxetine
hydrochloride) should not be used in children and adolescents under
18 years of age (ie. Pediatric patients), due to a possible increased
risk of suicide-related adverse events in this patient population.
|